Haemonetics Corporation HAE

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.

HAE hizo una división de acciones (split) de 2:1 el 3 de diciembre de 2012: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 18 sept

  PAHC vs. HAE: Which Stock Should Value Investors Buy Now?

  In a comparison of two Medical-Products sector stocks, Phibro Animal Health (PAHC) emerges as the better value opportunity compared to Haemonetics (HAE). PAHC holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a forward P/E of 10.06 and PEG ratio of 1.02. HAE has a Zacks Rank #3 (Hold) with a Value grade of C, showing a forward P/E of 20.36 and PEG ratio of 2.15, making PAHC more attractive to value investors.

  

• Zacks Investment Research 31 ago

  GEHC vs. HAE: Which Stock Is the Better Value Option?

  In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive value investment option compared to Haemonetics (HAE). GEHC holds a Zacks Rank #2 (Buy) with a Value grade of B, featuring a lower forward P/E ratio of 14.54 and P/B ratio of 2.95. HAE, ranked #3 (Hold) with a Value grade of C, has a higher forward P/E of 19.67 and P/B of 5.64, suggesting GEHC offers better value metrics and a more improving earnings outlook.

  

• GlobeNewswire Inc. 24 jul

  Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies

  The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, with a CAGR of 7.9%. Growth is driven by rising prevalence of autoimmune and neurological diseases, increased demand for plasma-derived therapies, and technological advances in automated systems. Disposables lead the product segment while plasmapheresis dominates procedures. North America holds the largest regional market share. Key challenges include high procedural costs and limited adoption in emerging markets.

  

• GlobeNewswire Inc. 24 jun

  [Latest] Global Therapeutic Apheresis Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

  The global therapeutic apheresis market is projected to grow from USD 3.84 billion in 2025 to USD 8.94 billion by 2035, at a CAGR of 7.9%. Growth is driven by increased prevalence of chronic and autoimmune diseases, technological advancements in automated systems, and improved reimbursement policies. Key players include Terumo BCT, Fresenius Kabi, Haemonetics, and B. Braun Melsungen.